Leandro Cerchietti

My laboratory is committed to transforming lymphoma research into better, more personalized treatments for patients. We study the genetic, epigenetic, metabolic, and microenvironmental factors that drive lymphoma growth and treatment response, with the goal of moving discoveries rapidly from the lab to the clinic. Our research has already helped move new ideas into clinical trials. Our work has helped launch clinical trials, identify biomarkers to guide patient selection, and advance innovative strategies such as epigenetic priming to make chemotherapy, immunotherapy, and targeted therapies more effective. We also contributed key preclinical findings that supported the development of FDA-approved compounds for relapsed/refractory lymphoma. More recently, we developed a new microenvironment-based classification of B-cell lymphoma that has already improved treatment selection and outcomes in clinical trials.